NORRIS MEDICINES LTD.

Norris Medicines Ltd has announced that its Board of Directors will convene on November 14, 2026, to consider and approve the Un-audited Financial Results for the quarter and half-year ended September 30, 2026. The meeting will also include a review of the Limited Review Report. Concurrently, the company has maintained its trading window closure for securities from October 1, 2026, until 48 hours post the declaration of these financial results, in line with SEBI's insider trading regulations.

Norris Medicines Ltd held its 35th Annual General Meeting (AGM) on September 29, 2026, conducted via video conferencing. The company announced that all resolutions presented to shareholders were passed with the requisite majority. The voting results and the scrutinizer's report, dated September 29, 2026, confirm the successful passage of all agenda items. The AGM utilized remote e-voting and an e-voting facility during the meeting, managed by Purva Sharegistry India Pvt. Ltd. The cut-off date for determining voting eligibility was September 22, 2026.

Norris Medicines Limited conducted its 35th Annual General Meeting (AGM) on Tuesday, September 29, 2026, via Video Conferencing. The meeting, which commenced at 2:30 PM IST and concluded at 2:45 PM IST, addressed several key agenda items. These included the adoption of Audited Financial Statements for the year ended March 31, 2026, the re-appointment of a director retiring by rotation, and special business concerning the appointment of Mr. Vimal D. Shah as Managing Director. Additionally, resolutions were passed regarding an increase in borrowing limits, authorization for the disposal of the company's undertaking, and enhancement of limits under Section 186 of the Companies Act, 2013. The results of the e-voting will be announced within two working days.

Norris Medicines Limited conducted its 35th Annual General Meeting (AGM) on September 29, 2026, via video conferencing. The meeting, which commenced at 2:30 PM IST and concluded at 2:45 PM IST, addressed several key agenda items. These included the adoption of audited financial statements for the year ended March 31, 2026, the re-appointment of a director retiring by rotation, and special business concerning the appointment of Mr. Vimal D. Shah as Managing Director. Additionally, resolutions were proposed to increase borrowing limits, authorize the disposal of the company's undertaking, and enhance limits under Section 186 of the Companies Act, 2013. The results of the e-voting will be announced within two working days.

Norris Medicines Ltd has announced the closure of its trading window for designated persons, including promoters, directors, auditors, and key managerial personnel, effective October 1, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain in effect until 48 hours after the declaration of the un-audited financial results for the quarter ending September 30, 2026. The company will announce the date of the board meeting to approve these results in due course. Designated individuals are prohibited from trading in the company's securities during this period.

Norris Medicines Ltd has announced its 35th Annual General Meeting (AGM) for the Financial Year 2025-26. The meeting is scheduled for Tuesday, September 29, 2026, at 02:30 PM IST, and will be conducted via Video Conference/Other Audio-Visual Means (VC/OAVM). The company has also provided details for remote e-voting, with the cut-off date for eligibility being September 22, 2026. Remote e-voting will commence on September 26, 2026, and conclude on September 28, 2026. The Annual Report for FY 2025-26, along with the AGM notice, is available on the company's website, the BSE India website, and the Purva Sharegistry website.

Norris Medicines Ltd has filed its 35th Annual Report for the financial year 2025-26, as per SEBI regulations. The report, sent electronically to shareholders, is also available on the company's website. It includes the Board's Report, Secretarial Audit Report, Management Discussion and Analysis, financial statements (Balance Sheet, Profit & Loss, Cashflow), and auditor's report. The Annual General Meeting (AGM) is scheduled for September 29, 2026, to adopt the audited financial statements for the year ended March 31, 2026, and to re-appoint Mr. Praveen J. Bafna as Director. Additionally, a special resolution will be considered for the appointment of Mr. Vimal D. Shah as Managing Director.

Norris Medicines Ltd announced the outcome of its Board Meeting held on September 3, 2026. The board approved the Directors Report for the Financial Year ended 2025-2026, along with related annexures. Key decisions included approving the closure of the Register of Members and Share Transfer Books for the upcoming Annual General Meeting (AGM). The company also approved the cut-off date for electronic voting entitlements and the convening of the 35th AGM on September 29, 2026, to be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The 35th Annual Report, including the AGM notice, was also approved. Furthermore, the board appointed Mr. Hemant Shetye as the scrutinizer for the e-voting process and Purva Sharegistry (India) Pvt. Ltd. to facilitate e-voting at the AGM. Directors and the Company Secretary were authorized to conduct the AGM and manage related documentation.

Norris Medicines Limited announced the appointment of Mr. Vimal Dhirendra Shah (DIN: 01506655) as Managing Director for a term of three years, effective September 1, 2026, until August 31, 2029. This reappointment is subject to shareholder approval. Mr. Shah, a commerce graduate with over 15 years of business management experience, also serves on the Audit Committee and Stakeholders Relationship Committee. The company also reported its un-audited financial results for the quarter ended June 30, 2026, showing a net loss of ₹39.68 lakhs. The Board of Directors approved these results and the appointment during their meeting held on August 14, 2026.

Norris Medicines Limited announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors also approved the appointment of Mr. Vimal Dhirendra Shah as Managing Director for a term of three years, effective September 1, 2026, subject to shareholder approval. The company is arranging to publish the financial results in newspapers as per SEBI regulations. The board meeting commenced at 3:00 PM and concluded at 4:00 PM.